ASCO Annual Meeting: Street Team | Conference

Petros Grivas, MD, PhD, on Future Updates to the COVID-19 and Cancer Consortium
July 09, 2020

Data from the registry suggested that in patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death.

Petros Grivas, MD, PhD, on Advice for Patients with Cancer During the COVID-19 Pandemic
July 05, 2020

The expert oncologist discussed the findings of the COVID-19 and Cancer Consortium and how the results of the consortium should inform conversations with patients with cancer.

Alex Spira, MD, PhD, FACP, Discusses Novel Agent in Multiple Tumor Types
June 17, 2020

An investigational PD-L1 PROBODY therapeutic, CX-072, demonstrated durable responses and appeared tolerable in patients across multiple tumor types.

Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer Care
June 15, 2020

Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with non-small cell lung cancer.

Zsofia K. Stadler, MD, on the Importance of Germline Analyses in Advanced Cancer
June 03, 2020

Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics.

Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial
June 03, 2020

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.